The problem, which affects one in 500 children in Britain, occurs when the immune system mistakenly attacks cells in the pancreas, stopping it from producing the hormone insulin.
Mahn Singh is the first British child to be part of a trial for a new drug, teplizumab, which blocks the immune system malfunction that destroys insulin-producing cells and causes type 1 diabetes.